Suchergebnisse - "Waalewijn, Hylke"

PubPharm (15)

1

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

enthalten in: HIV medicine | 2023

von Ambrosioni, J. | Levi, L. | Alagaratnam, J. | +18

2

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus : Results From the CHAPAS4 Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Bevers, L. | Waalewijn, H. | Szubert, A. | +10

3

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

enthalten in: Clinical pharmacokinetics | 2023

von Chandasana, H. | Thapar, M. | Hayes, S. | +21

4

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children : A Substudy of the CHAPAS-4 Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waalewijn, H. | Szubert, A. | Wasmann, R. | +18

5

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

enthalten in: Clinical pharmacokinetics | 2023

von Chandasana, H. | Thapar, M. | Hayes, S. | +20

6

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

enthalten in: HIV Medicine | 2023

von Ambrosioni, J. | Levi, L. | Alagaratnam, J. | +17

7

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

enthalten in: AIDS (London, England) | 2022

von Waalewijn, H. | Stol, K. | van der Knaap, L. | +7

8

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

enthalten in: HIV medicine | 2022

von Ryom, L. | De Miguel, R. | Cotter, A. | +19

9

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis : a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

enthalten in: The lancet. HIV | 2022

von Turkova, A. | Waalewijn, H. | Chan, M. | +121

CommentIn: Lancet HIV. 2022 Sep;9(9):e599-e600. - PMID 35868340

10

Dolutegravir dosing for children with HIV weighing less than 20 kg : pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

enthalten in: The lancet. HIV | 2022

von Waalewijn, H. | Chan, M. | Bollen, P. | +18